Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2013

View Archived Issues

Novel antibody-drug conjugate for drug-resistant blood cancer tested in preclinical studies

Gilead Sciences presents further clinical data on Stribild

Scripps Research Institute designs dual JNK3/LRRK2 inhibitor

Effective treatment of pancreatic ductal carcinoma xenografts with CBL-0137

Final results of the IMPACT trial of the TLR9 agonist MGN-1703 reported

Sanofi discovers novel FGFR inhibitors

DBV Technologies completes enrollment in VIPES study of peanut allergy

Researchers present phase II results for famitinib in nasopharyngeal carcinoma

Margetuximab well tolerated and active in phase I solid tumors trial

Secukinumab demonstrates superiority to Enbrel in head-to-head phase III study

Bayer begins phase III trial of BAY-94-9027 in children with hemophilia A

Novartis and Biological E to deliver typhoid and paratyphoid vaccines to developing world

Capricor and Nile Therapeutics sign merger agreement

Bayer discloses new FGFR inhibitors for cancer

Sanofi presents novel cannabinoid CB2 receptor ligands

Santaris Pharma licenses Locked Nucleic Acid technology to RaNA Therapeutics

Researchers in the U.K. patent new agents for bacterial infections

EMA accepts MAA for new insulin glargine biosimilar product

Oramed begins patient enrollment in phase IIa trial of ORMD-0801

La Jolla Pharmaceutical begins dosing in phase II trial of GCS-100 in chronic kidney disease

Scientists at Receptos synthesize novel GLP-1 receptor modulators

Phase II study of C. difficile vaccine initiated in Japan

GSK files supplemental NDAs for combination of dabrafenib and trametinib in metastatic melanoma

Novavax commences phase I trial of A(H7N9) influenza vaccine candidate

AstraZeneca enters oncology collaboration with Cambridge medical research institutions

FDA clears Signum Dermalogix's IND application for SIG-990 in rosacea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...